IDEAS home Printed from https://ideas.repec.org/r/eee/respol/v32y2003i5p737-750.html

Alliances are not enough explaining rapid growth in biotechnology firms

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Kalle Pajunen & Joonas Järvinen, 2018. "To survive or succeed? An analysis of biotechnology firms," Small Business Economics, Springer, vol. 51(3), pages 757-771, October.
  2. Nancy Haskell & Sophie Veilleux & Donald Béliveau, 2016. "Functional and contextual dimensions of INVs’ alliance partner selection," Journal of International Entrepreneurship, Springer, vol. 14(4), pages 483-512, December.
  3. Anna Bialek-Jaworska & Renata Gabryelczyk & Agnieszka Pugaczewicz, 2016. "Determinants of Business Model Maturity (Determinanty dojrzalosci modeli biznesowych)," Research Reports, University of Warsaw, Faculty of Management, vol. 1(20), pages 7-23.
  4. Stephen Roper & Helen Xia, 2014. "Unpacking open innovation: Absorptive capacity, exploratory and exploitative openness and the growth of entrepreneurial biopharmaceutical firms," Research Papers 0019, Enterprise Research Centre.
  5. Jorge Niosi, 2009. "Bridging Canadian Technology SMEs Over the Valley of Death," International Productivity Monitor, Centre for the Study of Living Standards, vol. 18, pages 80-84, Spring.
  6. Katia Angue & Cécile Ayerbe & Liliana Mitkova, 2014. "A method using two dimensions of the patent classification for measuring the technological proximity: an application in identifying a potential R&D partner in biotechnology," The Journal of Technology Transfer, Springer, vol. 39(5), pages 716-747, October.
  7. Hasan Bakhshi & John Edwards & Stephen Roper & Judy Scully & Duncan Shaw & Lorraine Morley & Nicola Rathbone, 2013. "An Experimental Approach to Industrial Policy Evaluation: The case of Creative Credits," Research Papers 0004, Enterprise Research Centre.
  8. David Bendig & Simon Hensellek & Julian Schulte, 2024. "Beneficial, Harmful, or Both? Effects of Corporate Venture Capital and Alliance Activity on Product Recalls," Entrepreneurship Theory and Practice, , vol. 48(1), pages 35-70, January.
  9. Jane Marceau, 2007. "Bringing science to life in Australia: the need for a new approach in human health biotechnology policy," The Journal of Technology Transfer, Springer, vol. 32(4), pages 303-327, August.
  10. Johan Wiklund & Dean A. Shepherd, 2009. "The Effectiveness of Alliances and Acquisitions: The Role of Resource Combination Activities," Entrepreneurship Theory and Practice, , vol. 33(1), pages 193-212, January.
  11. Białek-Jaworska Anna & Dobroszek Justyna, 2019. "R&D Expenditure and the Role of Scientists," Financial Sciences. Nauki o Finansach, Sciendo, vol. 24(2), pages 1-16, June.
  12. Stephen Roper & Helen Xia, 2014. "Innovation, innovation strategy and survival," Research Papers 0017, Enterprise Research Centre.
  13. Rammer, Christian & Ohmstedt, Jörg & Binz, Hanna L. & Heneric, Oliver, 2006. "Unternehmensgründungen in der Biotechnologie in Deutschland 1991 bis 2004," ZEW Dokumentationen 06-03, ZEW - Leibniz Centre for European Economic Research.
  14. Luukkonen, Terttu, 2005. "Variability in organisational forms of biotechnology firms," Research Policy, Elsevier, vol. 34(4), pages 555-570, May.
  15. Häussler, Carolin, 2006. "Can’t Buy Me Rights! The Contractual Structure of Asymmetrical Inter-firm Collaborations," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 189, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
  16. Chi-Yo Huang & I-Ling Tung, 2020. "Strategies for Heterogeneous R&D Alliances of In Vitro Diagnostics Firms in Rapidly Catching-Up Economies," IJERPH, MDPI, vol. 17(10), pages 1-34, May.
  17. F. Stam & Neil Thompson & Andrea Herrmann & Marko Hekkert, 2011. "Innovation barriers for small biotech, ICT and clean tech firms:Coping with knowledge leakage and legitimacy deficits," Scales Research Reports H201115, EIM Business and Policy Research.
  18. Mayer-Haug, Katrin & Read, Stuart & Brinckmann, Jan & Dew, Nicholas & Grichnik, Dietmar, 2013. "Entrepreneurial talent and venture performance: A meta-analytic investigation of SMEs," Research Policy, Elsevier, vol. 42(6), pages 1251-1273.
  19. Erik Stam & Karl Wennberg, 2009. "The roles of R&D in new firm growth," Small Business Economics, Springer, vol. 33(1), pages 77-89, June.
  20. Xia Wang, 2005. "Technological Characteristics and R&D Alliance Form: Evidence from the U.S. Biotechnology Industry," Working papers 2005-35, University of Connecticut, Department of Economics.
  21. Luukkonen, Terttu, 2003. "Variability in Forms of Organisation in Biotechnology Firms," Discussion Papers 872, The Research Institute of the Finnish Economy.
  22. Apostolos Vetsikas & Yeoryios Stamboulis, 2023. "A conceptual framework for modeling heterogeneous actors' behavior in national innovation systems," Journal of Evolutionary Economics, Springer, vol. 33(3), pages 773-796, July.
  23. Heide Fier & Andreas Pyka, 2014. "Against the one-way-street: analyzing knowledge transfer from industry to science," The Journal of Technology Transfer, Springer, vol. 39(2), pages 219-246, April.
  24. Belussi, Fiorenza & Sammarra, Alessia & Sedita, Silvia Rita, 2010. "Learning at the boundaries in an "Open Regional Innovation System": A focus on firms' innovation strategies in the Emilia Romagna life science industry," Research Policy, Elsevier, vol. 39(6), pages 710-721, July.
  25. Mc Namara, Peter & Baden-Fuller, Charles, 2007. "Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms," Research Policy, Elsevier, vol. 36(4), pages 548-565, May.
  26. Cacciolatti, Luca & Lee, Soo Hee, 2016. "Revisiting the relationship between marketing capabilities and firm performance: The moderating role of market orientation, marketing strategy and organisational power," Journal of Business Research, Elsevier, vol. 69(12), pages 5597-5610.
  27. Céline Bérard & Marie Perez, 2014. "Alliance Dynamics through Real Options: The Case of an Alliance between Competing Pharmaceutical Companies," Post-Print hal-04010373, HAL.
  28. Fabio Sorrentino & Francesco Garraffo, 2012. "Explaining performing R&D through alliances: Implications for the business model of Italian dedicated biotech firms," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 16(3), pages 449-475, August.
  29. Terje Grønning, 2007. "Biotechnology business in Norway: Peripheral advantage, or just periphery?," Working Papers on Innovation Studies 20070607, Centre for Technology, Innovation and Culture, University of Oslo.
  30. Jorge Niosi, 2010. "Building National and Regional Innovation Systems," Books, Edward Elgar Publishing, number 14006, June.
  31. Morreale, Azzurra & Robba, Serena & Lo Nigro, Giovanna & Roma, Paolo, 2017. "A real options game of alliance timing decisions in biopharmaceutical research and development," European Journal of Operational Research, Elsevier, vol. 261(3), pages 1189-1202.
  32. Valérie Sabatier & Vincent Mangematin & Tristan Rouselle, 2010. "From Business model to Business model portfolio in the european biopharmaceutical industry," Post-Print hal-00430782, HAL.
  33. Bérard, Céline & Perez, Marie, 2014. "Alliance dynamics through real options: The case of an alliance between competing pharmaceutical companies," European Management Journal, Elsevier, vol. 32(2), pages 337-349.
  34. Petra Gibcus & F. Stam, 2012. "Firm resources, dynamic capabilities, and the early growth of firms," Scales Research Reports H201219, EIM Business and Policy Research.
  35. Avenel, E. & Corolleur, F. & Gauthier, C. & Rieu, C., 2005. "Start-ups, firm growth and the consolidation of the French biotech industry," Working Papers 200503, Grenoble Applied Economics Laboratory (GAEL).
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.